AKAM vs MYGN · P/E 27, rev $2.17B vs rev $824.5M
Akamai Technologies Inc (AKAM) versus Myriad Genetics Inc (MYGN) — a side-by-side from cached financials, not a winner call.
Akamai Technologies Inc (AKAM) is a software - infrastructure company listed on US.
Myriad Genetics Inc (MYGN) is a diagnostics & research company listed on NASDAQ.
Latest reported AKAM revenue for 2026-06-30 was $2.17B. Net income was $185.7M. AKAM currently screens at market cap $11.31B and trailing P/E 26.7.
Latest reported MYGN revenue for 2025-12-31 was $824.5M. Net income was -$365.9M. Revenue was down 1.6% from 2024-12-31 to 2025-12-31. MYGN currently screens at market cap $413.7M.
AKAM currently screens at market cap $11.31B and trailing P/E 26.7. MYGN currently screens at market cap $413.7M.
Not investment advice. Open the AKAM and MYGN stock pages for the full models.
Not investment advice.